Clinical trial NCT01560923: Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer
Official title: A Randomized, Double-Blind Phase II Study of Sipuleucel-T (Provenge®) Followed by Indoximod or Placebo in the Treatment of Patients With Asymptomatic or Minimally Symptomatic Metastatic Castration Resistant Prostate Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Metastatic Prostate Cancer
Keywords: hormone refractory prostate cancer
Lead sponsor: Masonic Cancer Center, University of Minnesota
Sponsor class: OTHER
First posted: 2012-03-22
Enrollment: 47
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a randomized, double blind, multi-institutional phase II therapeutic study of Indoximod or placebo after the completion of standard of care sipuleucel-T (Provenge®) in men with asymptomatic or minimally symptomatic metastatic prostate cancer that is castration resistant (hormone refractory). Patients are randomized to receive either twice daily oral Indoximod or placebo for 6 months beginning the day after the third and final sipuleucel-T infusion.

Detailed description: Sipuleucel-T will be administered as standard of care. Oral Indoximod/placebo will be self-administered twice daily for 6 months starting after the last infusion of sipuleucel-T. Patients will be treated for a minimum of 12 weeks of Indoximod/placebo before disease progression can be declared and Indoximod/placebo will not be discontinued for increasing prostate specific antigen (PSA) in the absence of symptomatic clinical progression.

Eligibility criteria: Inclusion Criteria:

* Histologically documented adenocarcinoma of the prostate with metastatic disease as evidenced by soft tissue and/or bony metastases on baseline computed tomography (CT) scan of the abdomen and pelvis and/or bone scan
* Castration-resistant based on a current or historical evidence of disease progression despite surgical or medical castration as demonstrated by one or more of the following:

  * PSA progression (defined as two consecutive prostate specific antigen (PSA) measurements at least 14 days apart ≥ 2.0 ng/ml and ≥ 50% above the minimum PSA during castration therapy or above pre-treatment value if no response)
  * progression of measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) criteria (≥ 50% increase in the sum of the cross products of all measurable lesions or the development of any new lesions
  * progression of non-measureable disease
* Serum PSA ≥ 2.0 ng/ml at study enrollment
* Castration levels of testosterone defined as ≤ 30 ng/dL at study enrollment. Must be at least 3 months from surgical castration or must have received medical castration therapy for at least 3 months and be receiving such therapy at the time of confirmed disease progression
* Asymptomatic or minimally symptomatic disease as demonstrated by Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 and no need for opiate pain medications to control pain/symptoms
* Age 18 years and old
* Adequate bone marrow, renal and hepatic function within 14 days of study enrollment defined as:

  * Bone marrow: WBC \> 3,000/uL; absolute neutrophil count \> 1,500/uL; platelets \> 100,000/uL
  * Renal: creatinine within institutional upper limit of normal (ULN) OR creatinine clearance \> 60 mL/min/1.73 m2 for patients with creatinine levels above ULN
  * Hepatic: total bilirubin \< 1.5 X institutional ULN; aspartate aminotransferase (AST ((SGOT)) and alanine aminotransferase (ALT((SGPT)) \< 2.5 X institutional ULN

Exclusion Criteria:

* Chronic steroid dependence (should stop all steroid supplementation 4 weeks prior to enrollment)
* Human immunodeficiency virus (HIV)-positive patients and those with other acquired/inherited immunodeficiency
* History of gastrointestinal disease causing malabsorption or obstruction such as, but not limited to Crohn's disease, celiac sprue, tropical sprue, bacterial overgrowth/blind loop syndrome, gastric bypass surgery, strictures, adhesions, achalasia, bowel obstruction, or extensive small bowel resection
* Inability to take medications by mouth
* History of allergic reactions attributed to compounds of similar chemical or biologic composition
* Active autoimmune disease, chronic inflammatory condition, conditions requiring concurrent use of any systemic immunosuppressants or steroids. Mild-intermittent asthma requiring only occasional beta-agonist inhaler use or mild localized eczema will not be excluded.
* Previous allo-transplant of any kind
* History of prior treatment with anti-CTLA4 blocking antibody

Primary outcomes:
measure: Immune Response to Sipuleucel-T
timeFrame: 14 Weeks from First Leukapheresis
Secondary outcomes:
measure: Number of Participants With Progression Free Survival at 6 Months
timeFrame: 6 Months
measure: Objective Response Rate
timeFrame: 4 weeks
measure: Overall Survival
timeFrame: 2 years
measure: Quality of Life Scale Results
timeFrame: 6 Months
measure: Ratio of Antibodies to PA2024
timeFrame: 14 Weeks from First Leukapheresis
Other outcomes:
Locations:
city: Chicago
country: United States
facility: University of Illinois Medical Center
state: Illinois
city: Minneapolis
country: United States
facility: Masonic Cancer Center, University of Minnesota
state: Minnesota
city: New York
country: United States
facility: New York Presbyterian/Weill Cornell Medical Center
state: New York
city: Hershey
country: United States
facility: Penn State Milton S. Hershey Medical Center
state: Pennsylvania
Study officials:
affiliation: Masonic Cancer Center, University of Minnesota
name: Shilpa Gupta, M.D.
role: PRINCIPAL_INVESTIGATOR
References: